Research Article
Serum Sclerostin as a Possible Biomarker in Ankylosing Spondylitis: A Case-Control Study
Table 1
The main demographic clinical and X-ray features of AS patients (
).
| | Male/female | 30/10 |
| | Age (median/25th–75th percentile) year | 50 (40.5–56.75) | | Disease duration (median/25th–75th percentile) year | 12.5 (6.2–21.5) | | HLA-B27, n (%) | 28 (70) | | CRP, mg/dl (median/25th–75th percentile) | 0.5 (0.2–0.9) | | ESR mm/hr (median/25th–75th percentile) | 12.5 (5–20.7) | | VAS global health (median/25th–75th percentile) | 4.75 (3–5.9) | | VAS physician (median/25th–75th percentile) | 4 3–5 | | ASDAS-CRP (median/25th–75th percentile) | 2.1 (1.5–3.3) | | ASDAS-ESR (median/25th–75th percentile) | 2.2 (1.4–3.25) | | BASDAI (median/25th–75th percentile) | 3.65 (2–5.2) | | BASMI (median/25th–75th percentile) | 2 (1–5) | | BASFI (median/25th–75th percentile) | 1.65 (1–3.9) | | Sacroileitis IV grade, n (%) | 14 (35) | | Sacroileitis II-III grade, n (%) | 26 (65) | | mSASSS (median/25th–75th percentile) | 10 (2.5–29.5) | | Peripheral involvement (%) | 14 (35) | | Enthesitis, n (%) | 12 (30) | | Psoriasis, n (%) | 3 (7.5) | | Inflammatory bowel disease, n (%) | 5 (12.5) | | Uveitis, n (%) | 9 (22.5) | | Treatment, n (%) | | | NSAIDs | 17 (42.5) | | DMARDs | 6 (15) | | Anti-TNF | 22 (55) |
|
|
CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; VAS: visual analogic scale; ASDAS: Ankylosing Spondylitis Disease Activity Score; BASMI: Bath Ankylosing Spondylitis Metrology Index; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; BASFI: Bath Ankylosing Spondylitis Functional Index; mSASSS: Stoke Ankylosing Spondylitis Spinal Score: DMARDs: disease-modifying antirheumatic drugs; NSAIDs: nonsteroidal anti-inflammatory drugs; TNF: tumor necrosis factor.
|
